DOP2012000170A - Proceso para la fabricacion de un agente farmaceuticamante activo - Google Patents

Proceso para la fabricacion de un agente farmaceuticamante activo

Info

Publication number
DOP2012000170A
DOP2012000170A DO2012000170A DO2012000170A DOP2012000170A DO P2012000170 A DOP2012000170 A DO P2012000170A DO 2012000170 A DO2012000170 A DO 2012000170A DO 2012000170 A DO2012000170 A DO 2012000170A DO P2012000170 A DOP2012000170 A DO P2012000170A
Authority
DO
Dominican Republic
Prior art keywords
manufacture
active pharmaceutically
pharmaceutically agent
agent
active
Prior art date
Application number
DO2012000170A
Other languages
English (en)
Inventor
Svend Treppendahl
Frans Therkelsen
Michael Harold Rock
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of DOP2012000170A publication Critical patent/DOP2012000170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Se revelan aquí los procesos para la preparación de un agente farmacéuticamente activo y las saies farmacéuticamente aceptables del mismo.
DO2012000170A 2009-12-23 2012-06-18 Proceso para la fabricacion de un agente farmaceuticamante activo DOP2012000170A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
DOP2012000170A true DOP2012000170A (es) 2012-08-31

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000170A DOP2012000170A (es) 2009-12-23 2012-06-18 Proceso para la fabricacion de un agente farmaceuticamante activo

Country Status (37)

Country Link
US (3) US8461353B2 (es)
EP (1) EP2516394B1 (es)
JP (2) JP5864435B2 (es)
KR (2) KR101873182B1 (es)
CN (2) CN102656146B (es)
AR (1) AR079580A1 (es)
AU (1) AU2010335659B2 (es)
BR (1) BR112012015749A2 (es)
CA (1) CA2785440C (es)
CL (1) CL2012001725A1 (es)
CR (1) CR20120316A (es)
CY (1) CY1118032T1 (es)
DK (1) DK2516394T3 (es)
DO (1) DOP2012000170A (es)
EA (1) EA021440B1 (es)
ES (1) ES2575666T3 (es)
GE (1) GEP20146078B (es)
HK (2) HK1174921A1 (es)
HR (1) HRP20160518T1 (es)
HU (1) HUE028806T2 (es)
IL (2) IL220329A (es)
MA (1) MA33945B1 (es)
ME (1) ME02401B (es)
MX (1) MX2012007078A (es)
MY (1) MY159251A (es)
NZ (2) NZ625798A (es)
PL (1) PL2516394T3 (es)
PT (1) PT2516394E (es)
RS (1) RS54820B1 (es)
SG (1) SG181910A1 (es)
SI (1) SI2516394T1 (es)
SM (1) SMT201600166B (es)
TN (1) TN2012000279A1 (es)
TW (1) TW201139370A (es)
UA (1) UA111584C2 (es)
WO (1) WO2011076212A2 (es)
ZA (1) ZA201305936B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
SG11201704523WA (en) 2014-12-12 2017-07-28 H Lundbeck As A process for the manufacture of idalopirdine
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
WO2017174691A1 (en) 2016-04-08 2017-10-12 H. Lundbeck A/S A process for the manufacture of idalopirdine via hydrogenation of an imine
EP3333154A1 (en) * 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist
WO2020136188A1 (en) * 2018-12-27 2020-07-02 F. Hoffmann-La Roche Ag Process for the preparation exo-tert-butyl n-(3-azabicyclo[3.2.1]octan-8-yl)carbamate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) * 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
DE69413560T2 (de) 1993-12-28 1999-04-22 Rhodia Fiber & Resin Intermediates, Courbevoie Verfahren zur herstellung eines katalysators für die hydrierung von nitrilen in aminen und verwendung dieses katalysators in der hydrierung
JP3340439B2 (ja) 1993-12-28 2002-11-05 ローヌ−プーラン シミ ドーピングさせたラニーニッケル型の触媒の存在におけるニトリルの、アミンへの接触水素添加方法
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
JP2001508197A (ja) 1997-10-31 2001-06-19 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 構成信号にノイズを加算してｌｐｃ原理により符号化された音声のオーディオ再生のための方法及び装置
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
DK1379239T3 (da) * 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
AU2006325815B2 (en) * 2005-12-15 2012-07-05 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2736880A1 (en) 2008-09-26 2010-04-01 Wyeth Llc 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) * 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
HRP20160518T1 (hr) 2016-06-03
US8461353B2 (en) 2013-06-11
IL220329A0 (en) 2012-08-30
IL231141A0 (en) 2014-03-31
HK1196352A1 (en) 2014-12-12
IL231141A (en) 2016-03-31
US9382205B2 (en) 2016-07-05
RS54820B1 (sr) 2016-10-31
TW201139370A (en) 2011-11-16
CN102656146B (zh) 2014-12-17
CA2785440A1 (en) 2011-06-30
JP5864435B2 (ja) 2016-02-17
EP2516394A2 (en) 2012-10-31
BR112012015749A2 (pt) 2015-09-15
CY1118032T1 (el) 2017-05-17
AU2010335659A1 (en) 2012-07-05
MX2012007078A (es) 2012-07-20
DK2516394T3 (en) 2016-06-13
SG181910A1 (en) 2012-08-30
IL220329A (en) 2016-03-31
SMT201600166B (it) 2016-07-01
WO2011076212A3 (en) 2011-08-11
CL2012001725A1 (es) 2012-11-30
GEP20146078B (en) 2014-04-10
KR101796330B1 (ko) 2017-11-09
MA33945B1 (fr) 2013-01-02
MY159251A (en) 2016-12-30
AR079580A1 (es) 2012-02-01
EA021440B1 (ru) 2015-06-30
TN2012000279A1 (en) 2013-12-12
US20110152539A1 (en) 2011-06-23
JP2013515683A (ja) 2013-05-09
US20150080584A1 (en) 2015-03-19
JP6195605B2 (ja) 2017-09-13
EA201290552A1 (ru) 2012-12-28
KR101873182B1 (ko) 2018-06-29
HK1174921A1 (en) 2013-06-21
PT2516394E (pt) 2016-06-07
CR20120316A (es) 2012-08-16
US8901318B2 (en) 2014-12-02
CA2785440C (en) 2018-05-01
NZ625798A (en) 2014-10-31
ZA201305936B (en) 2015-09-30
WO2011076212A2 (en) 2011-06-30
ES2575666T3 (es) 2016-06-30
CN103694161A (zh) 2014-04-02
EP2516394B1 (en) 2016-03-16
PL2516394T3 (pl) 2016-09-30
NZ600639A (en) 2014-07-25
ME02401B (me) 2016-09-20
SI2516394T1 (sl) 2016-07-29
CN103694161B (zh) 2015-09-09
CN102656146A (zh) 2012-09-05
AU2010335659B2 (en) 2015-05-21
HUE028806T2 (en) 2017-01-30
UA111584C2 (uk) 2016-05-25
US20130245281A1 (en) 2013-09-19
KR20170125417A (ko) 2017-11-14
JP2016117734A (ja) 2016-06-30
KR20120112480A (ko) 2012-10-11

Similar Documents

Publication Publication Date Title
DOP2012000170A (es) Proceso para la fabricacion de un agente farmaceuticamante activo
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
GT201500069A (es) Piridinonas bicìclicas novedosas
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
PE20140255A1 (es) Tableta dispersable en forma oral
IN2013MU00711A (es)
ES2666382T8 (es) Ortesis activa para la rehabilitación neurológica del movimiento de los miembros inferiores, sistema que comprende dicha órtesis y proceso para poner en funcionamiento dicho sistema
MY191875A (en) Solid dosage form
WO2012103226A3 (en) Bendamustine formulations
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
IN2013MU01985A (es)
ECSP13012613A (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MY162688A (en) Oral care compositions
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla